The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-AstraZeneca says EU loses legal bid for more vaccine supplies by end-June

Fri, 18th Jun 2021 14:06

(Adds detail)

BRUSSELS/LONDON, June 18 (Reuters) - AstraZeneca
said on Friday the European Union had lost a legal case against
the pharmaceutical firm over the supply of COVID-19 vaccines,
with a court in Brussels rejecting an EU request for more
deliveries by the end of June.

But European Commission President Ursula von der Leyen said
Friday's ruling supported the EU's view that AstraZeneca --
against which the bloc has recently launched a second lawsuit --
had failed to meet its commitments.

The Anglo-Swedish pharmaceutical giant committed in a
contract to do its best to deliver 300 million doses to the
27-nation bloc by the end of June, but production problems led
the company to revise down its target to 100 million vaccines.

The supply cuts delayed the EU's vaccination drive in the
first quarter of the year, when the bloc had initially bet on
AstraZeneca to deliver the largest volume of its shots. That led
to a bitter dispute and to the EU's legal action to get at least
120 million doses by the end of June.

But AstraZeneca said a judge had ruled that it should
deliver only 80.2 million doses by a deadline of Sept. 27. The
company said it would "substantially exceed" that amount by the
end of June.

The court said in a statement that AstraZeneca must deliver
15 million doses by July 26, another 20 million by Aug. 23 and
another 15 million by Sept. 27, for a total of 50 million doses.

Should the company miss these deadlines it would face a
penalty of "10 euros ($11.8) per dose not delivered", the EU
Commission said.

AstraZeneca said other measures sought by the Commission had
been dismissed, and the court had found that the EU had no
exclusivity or right of priority over other parties the
drugmaker had contracts with.

"The judgment also acknowledged that the difficulties
experienced by AstraZeneca in this unprecedented situation had a
substantial impact on the delay," AstraZeneca said in a
statement.

"AstraZeneca now looks forward to renewed collaboration with
the European Commission to help combat the pandemic in Europe."

The European Union last month launched a second lawsuit
against the drugmaker seeking financial penalties for the delays
to vaccine supply.

"This decision confirms the position of the Commission:
AstraZeneca did not live up to the commitments it made in the
contract," Commission President von der Leyen said on Friday.
(Reporting by Francesco Guarascio in Brussels, Alistair Smout
in London, additional reporting by Muvija M in Bengaluru;
Editing by David Evans and Catherine Evans)

More News
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.